Diseases of Tetrapyrrole Metabolism - Refsum Disease and the Hepatic Porphyrias
- Author: Norman C Reynolds Jr, MD; Chief Editor: Stephen A Berman, MD, PhD, MBA more...
Background
Refsum disease and the hepatic porphyrias are rare inherited neurodegenerative conditions with exacerbations and remissions due to abnormal metabolism of large tetrapyrrole molecules.
Two common examples of large tetrapyrrole molecules are chlorophyll a, the photosynthetic pigment of green plants, and heme, the prosthetic group of hemoglobin (see the image below). Side groups on both species involve relatively small organic groups (methyl, vinyl, and free propionyl); 1 major exception is phytol, a large hydrocarbon alcoholic substituent on chlorophyll. Patients in both disease categories must avoid foods and drugs that lead to high levels of the relevant biological toxin, which can trigger or perpetuate an exacerbation.
Tetrapyrrole molecules are large-ringed structures developed from 4 pyrrole groups and used in energy metabolism in both plants and animals. Pathophysiology
The neurotoxin in Refsum disease is phytanic acid, which in affected individuals is stored in neural and visceral parenchyma because of a deficiency in phytanic acid alpha-hydroxylase. The source of phytanic acid is either direct absorption or conversion of absorbed phytol from ruminant fat in meat or milk (only ruminants can release phytol from chlorophyll during digestion). Homozygosity is required for significant phytanic acid build-up.
The hepatic porphyrias also are associated with neurological problems. The neurotoxins in these conditions are porphyrin precursors (delta-aminolevulinic acid [ALA], porphobilinogen [PBG]) and porphyrinogen substrates in heme synthesis, whose levels are elevated (see the image below). The actual porphyrins are oxidized products of the substrates, which are excreted in the feces and urine (the latter characterized by its reddish brown, fluorescent color.)
Three characteristic substrate molecules of the heme porphyrin pathway. Whereas the enzyme deficiency in Refsum disease is inherited in an autosomal-recessive pattern, the enzyme deficiencies involved in the hepatic porphyrias typically are inherited in an autosomal-dominant mode. The hepatic porphyrias account for a varying spectrum of upstream accumulations of porphyrins and porphyrin precursors specific to each type of porphyria. The following are common hepatic porphyrias:
- Acute intermittent porphyria (AIP) - Uroporphyrinogen synthase (or "porphobilinogen deaminase") deficiency with high ALA or PBG in urine and serum
- Hereditary coproporphyria - Coproporphyrinogen oxidase deficiency with high urinary and/or fecal levels of coproporphyrins
- Porphyria cutanea tarda (PCT) - Uroporphyrinogen decarboxylase deficiency with high urinary and red cell levels of uroporphyrin
- ALA dehydratase deficient porphyria (rare)
- Erythropoietic protoporphyria (EPP), "protoporphyria", or "erythrohepatic protoporphyria" (not a hepatic porphyria)[3, 4, 5]
- Ferrochelatase deficiency: Fecal and erythrocyte levels of protoporphyrins are increased without any urinary porphyrins.
- Abnormal porphyrin metabolism originates in erythrocytes, not the liver, yet ironically, patients with EPP may develop chronic liver failure.
- EPP is not characterized by neurologic symptoms and does not respond to sugar or hemin (ie, hematin) treatment.
Epidemiology
Frequency
United States
- Refsum disease is rare, but heterozygote carriers may be at risk if they eat diets highly selective for beef and dairy products.
- Acute intermittent porphyria incidence ranges from 5-10 per 100,000 (underestimated because of positive cases not being induced and long periods of latency). AIP is widely believed to be latent in 90% of cases.
- Porphyria cutanea tarda is believed to be the most common type, but because of poor recording, no data have been published.
- Erythropoietic protoporphyria is also believed to be common but not clearly documented.
- Other forms of true hepatic porphyrias are rare except variegate porphyria in individuals with ancestry of Afrikaner lineage.
International
It is the same as in the United States, but variegate porphyria is common in South Africa (about 3 cases per 1000 population).
Mortality/Morbidity
Both Refsum disease and hepatic porphyrias are characterized by remissions and exacerbations of neurologic dysfunction, which can resolve completely or manifest stepwise deterioration. Permanent residual deficits are not uncommon; residual defects during latent periods include polyneuropathy in both conditions, ataxia and retinitis pigmentosa with night blindness in Refsum disease,[6] and photosensitive dermatitis in porphyrias (rare in acute intermittent porphyria). Death in either disease is commonly caused by cardiac arrhythmias during exacerbations. Cardiomyopathy can occur in Refsum disease owing to phytanic acid storage and in acute porphyric crises owing to electrolyte disturbance (in as many as 25% of acute intermittent porphyria cases).
Race
- Both Refsum disease and the porphyrias tend to occur more often in individuals of white hereditary lineage. The exception is porphyria cutanea tarda, which is noted among blacks of Bantu lineage (as well as whites).
- Acute intermittent porphyria is most common among whites of English or Scandinavian heritage. Variegate porphyria is most common among Afrikaners, selectively concentrated in royal European lineage (eg, as documented in the popular film "The Madness Of King George"), and also present in certain large families of Great Britain, Holland, Sweden, and the United States.
Sex
Prevalence is expected to be equal between the sexes because of autosomal inheritance; however, clinical attacks may be more common in females with acute intermittent porphyria and in males with porphyria cutanea tarda. Consanguinity, causing the homozygous recessive condition, is not an uncommon cause of Refsum disease.
Age
Initial attacks in both disease categories can occur in early childhood, but in the hepatic porphyrias, the onset is usually postpubertal. Erythropoietic protoporphyria is characterized by childhood onset of acute cutaneous photosensitivity to direct sunlight.
- Childhood epilepsy is an exception to the postpuberty onset rule for initial porphyric attacks in the hepatic forms. Long-term drug use in idiopathic epilepsy with inactive or latent hepatic porphyria, even in prepubertal children, is a potent activator of cytochrome P450. Liver synthesis of heme groups is accelerated, leading to high levels of porphyrins and premature porphyric crises.
- Earlier onset Refsum disease is due to a pervasive dietary risk from consuming large quantities of beef and, to a greater degree, milk. For this same reason, persisting residual deficits are typical by age 20 years. Sporadic intake of provocative drugs in latent porphyria can induce exacerbations and eventually lead to persisting residual deficits.
Frank J, Christiano AM. Variegate porphyria: past, present and future. Skin Pharmacol Appl Skin Physiol. Nov-Dec 1998;11(6):310-20. [Medline].
Brenner DA, Bloomer JR. The enzymatic defect in variegate porphyria. Studies with human cultured skin fibroblasts. N Engl J Med. Apr 3 1980;302(14):765-9. [Medline].
Morais P, Mota A, Baudrier T, Trigo F, Oliveira JP, Cerqueira R, et al. Erythropoietic protoporphyria: a family study and report of a novel mutation in the FECH gene. Eur J Dermatol. Jul-Aug 2011;21(4):479-83. [Medline].
To-Figueras J, Ducamp S, Clayton J, Badenas C, Delaby C, Ged C, et al. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood. Aug 11 2011;118(6):1443-51. [Medline].
Wang Y, Langer NB, Shaw GC, Yang G, Li L, Kaplan J, et al. Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria. Exp Hematol. Jul 2011;39(7):784-94. [Medline]. [Full Text].
Kohlschütter A, Santer R, Lukacs Z, Altenburg C, Kemper MJ, Rüther K. A Child With Night Blindness: Preventing Serious Symptoms of Refsum Disease. J Child Neurol. Dec 7 2011;[Medline].
Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. Nov 2006;135(3):281-92. [Medline].
Felsher BF, Norris ME, Shih JC. Red-cell uroporphyrinogen decarboxylase activity in porphyria cutanea tarda and in other forms of porphyria. N Engl J Med. Nov 16 1978;299(20):1095-8. [Medline].
Reynolds NC Jr, Miska RM. Safety of anticonvulsants in hepatic porphyrias. Neurology. Apr 1981;31(4):480-4. [Medline].
Zadra M, Grandi R, Erli LC, et al. Treatment of seizures in acute intermittent porphyria: safety and efficacy of gabapentin. Seizure. Oct 1998;7(5):415-6. [Medline].
Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. Mar 15 2005;142(6):439-50. [Medline].
Anderson KE, Collins S. Open-label study of hemin for acute porphyria: clinical practice implications. Am J Med. Sep 2006;119(9):801.e19-24. [Medline].
Brodie MJ, Thompson GG, Moore MR, et al. Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood. Q J Med. Apr 1977;46(182):229-41. [Medline].
Eales L. The acute porphyria attack. 3. Acute porphyria: the precipitating and aggravating factors. S Afr Med J. Sep 25 1971;120-5. [Medline].
Goldberg A, Rimington C, Lochhead AC. Hereditary coproporphyria. Lancet. Mar 25 1967;1(7491):632-6. [Medline].
Hunter GH. Anesthetic considerations in hepatic porphyrias. CRNA. Feb 1999;10(1):6-14. [Medline].
Kappas A, Sassa S, Galbraith RA, et al. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, ed. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill; 1995:2103-2159.
King PH, Bragdon AC. MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria. Neurology. Aug 1991;41(8):1300-2. [Medline].
Lazarow PB, Moser HW. Disorders of peroxisome biogenesis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, ed. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill; 1995:2287-2324.
Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis. 1998;18(1):43-52. [Medline].
Redeker AG. Phlebotomy treatment of porphyria cutanea tarda: is it really effective?. Calif Med. Nov 1969;111(5):404-6. [Medline].
Tenhunen R, Mustajoki P. Acute porphyria: treatment with heme. Semin Liver Dis. 1998;18(1):53-5. [Medline].
Verhoeven NM, Wanders RJ, Poll-The BT, et al. The metabolism of phytanic acid and pristanic acid in man: a review. J Inherit Metab Dis. Oct 1998;21(7):697-728. [Medline].

